Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417129 | 0.88 | HSD17B10 (0.57) | CYP3A4HSD17B10GAALMNAKDM4E | |
| SCHEMBL1543332 | 0.88 | HSD17B10 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL320560 | 0.83 | CYP3A4 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14351002 | 0.83 | CYP3A4 (0.63) | CYP3A4HSD17B10LMNAKDM4ECA5A | |
| SCHEMBL13725392 | 0.81 | RXRA (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30031930 | 0.81 | TPMT (0.59) | HCAR1CYP3A4HSD17B10GAALMNA | |
| SCHEMBL10148962 | 0.81 | TPMT (0.59) | HCAR1CYP3A4HSD17B10GAALMNA | |
| SCHEMBL11703054 | 0.81 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL618766 | 0.81 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30597472 | 0.80 | CA1 (0.60) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3036234-A1 | DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Galapagos NV (BE) | 2016-06-29 | — | — | EP | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| WO-2015024905-A1 | DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015024905-A1 | DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-02-26 | — | — | WO | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | CA12 4839/4885CA1 4881/4885CA2 4289/4885 |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | CA12 579/4885CA1 1305/4885CA2 519/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | CA12 4482/4885CA1 4858/4885CA2 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.